You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 7,419,952


✉ Email this page to a colleague

« Back to Dashboard


Title:Use of exendins and agonists thereof to treat diabetes
Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Inventor(s): Beeley; Nigel Robert Arnold (Solana Beach, CA), Prickett; Kathryn S. (San Diego, CA), Bhavsar; Sunil (San Diego, CA), Young; Andrew A. (Rancho Santa Fe, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Mar 03, 2006
Application Number:11/368,225
Claims:1. A method for treating diabetes in a subject in need thereof comprising identifying a subject in need of treatment for diabetes and peripherally administering to the subject a therapeutically effective amount of an exending agonist analog, wherein the exending agonist analog has the amino acid sequence of: TABLE-US-00156 Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 (SEQ ID NO:4) Xaa.sub.8 Xaa.sub.9 Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Ala Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 Xaa.sub.22 Xaa.sub.23 Xaa.sub.24 Xaa.sub.25 Xaa.sub.26 Xaa.sub.27 Xaa.sub.28-Z.sub.1,

wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Asp or Glu; Xaa.sub.5 is Ala or Thr; Xaa.sub.6 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.7 is Thr or Ser; Xaa.sub.8 is Ala, Ser or Thr; Xaa.sub.9 is Asp or Glu; Xaa.sub.10 is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa.sub.11 is Ala or Ser; Xaa.sub.12 is Ala or Lys; Xaa.sub.13 is Ala or Gln; Xaa.sub.14 is Ala, Leu, Ile, pentylglycine, or Val; Xaa.sub.15 is Ala or Glu; Xaa.sub.16 is Ala or Glu; Xaa.sub.17 is Ala or Glu; Xaa.sub.19 is Ala or Val; Xaa.sub.20 is Ala or Arg; Xaa.sub.21 is Ala or Leu; Xaa.sub.22 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.24 is Ala, Glu or Asp; Xaa.sub.25 is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa.sub.26 is Ala or Leu; Xaa.sub.27 is Ala or Lys; Xaa.sub.28 is Ala or Asn; Z.sub.1 is --OH, TABLE-US-00157 --NH.sub.2, Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31 Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2 or Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2;

Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and Xaa.sub.38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and Z.sub.2 is --OH or --NH.sub.2; provided that no more than three of Xaa.sub.3, Xaa.sub.5, Xaa.sub.6, Xaa.sub.8, Xaa.sub.10, Xaa.sub.11, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, Xaa.sub.17, Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24, Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28, are Ala.

2. The method of claim 1, wherein said administration is by injection.

3. The method of claim 1, wherein said peripheral administration is intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal, or pulmonary.

4. The method of claim 1, further comprising administering an effective amount of at least one additional substance other than an exendin agonist analog that reduces food intake, appetite, body weight, obesity, or any combination thereof.

5. The method of claim 1, further comprising administering an effective amount of an amylin, an amylin agonist, a calcitonin, a leptin, a cholecystokinin, or a combination of two or more thereof.

6. The method of claim 1, further comprising administering an effective amount of [.sup.25,28,29Pro-]-human amylin.

7. The method of claim 1, wherein the diabetes is Type II diabetes.

8. The method of claim 1, wherein the exendin agonist analog is administered to the subject as a single or divided dose from 0.1 .mu.g/kg/day to 100 .mu.g/kg/day.

9. The method of claim 1, wherein the exendin agonist analog is administered at a dose of from 0.1 .mu.g/kg/day to 10 .mu.g/kg/day.

10. The method of claim 1, wherein the exendin agonist analog is administered at a dose of from 0.1 .mu.g/kg/day to 1 .mu.g/kg/day.

11. The method of claim 1, further comprising administering an effective amount of cholecystokinin octopeptide.

12. The method of claim 1, wherein: Xaa.sub.1 is His or Arg; Xaa.sub.2 is Gly or Ala; Xaa.sub.6 is Ala, Phe, or naphthylalanine; Xaa.sub.10 is Ala, Leu, or pentylglycine; Xaa.sub.14 is Ala, Leu, or pentylglycine; Xaa.sub.22 is Phe, or naphthylalanine; Xaa.sub.23 is Ile, Val, or tert-butylglycine; Xaa.sub.25 is Ala, Tm, or Phe; Z.sub.1 is --OH, TABLE-US-00158 --NH.sub.2, Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31 Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2 or Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2;

Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and Xaa.sub.38 are each independently Pro, homoproline, or N-methylalanine; and Z.sub.2 is --OH or --NH.sub.2; provided that no more than three of Xaa.sub.3, Xaa.sub.5, Xaa.sub.6, Xaa.sub.8, Xaa.sub.10, Xaa.sub.11, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, Xaa.sub.17, Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24, Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28, are Ala.

13. The method of claim 1, wherein: Xaa.sub.1 is His; Xaa.sub.2 is Gly; Xaa.sub.6 is Phe or naphthylalanine; Xaa.sub.14 is Leu, pentylglycine, or Met; Xaa.sub.22 is Phe or naphthylalanine; Xaa.sub.23 is Ile or Val; Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and Xaa.sub.38 are each independently Pro, homoproline, thioproline, or N-alkylalanine; and Z.sub.1 is --NH.sub.2.

14. The method of claim 1, wherein: Xaa.sub.14 is Leu or pentylglycine; and Xaa.sub.25 is Phe or naphthylalanine.

15. The method of claim 1, wherein Xaa.sub.31, Xaa.sub.36, Xaa.sub.37, and Xaa.sub.38 are each independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N--(C.sub.1-4 alkyl)glycine, N--(C.sub.1-4 alkyl)pentylglycine, or N--(C.sub.1-4 alkyl)alanine.

16. The method of claim 1, wherein the subject is a human.

17. The method of claim 1, wherein the exendin agonist analog has the amino acid sequence of SEQ ID NO. 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60.

18. The method of claim 1, wherein the diabetes is non-insulin dependent diabetes.

19. A method for treating diabetes in a human in need thereof comprising identifying a human in need of treatment for diabetes and peripherally administering to the human a therapeutically effective amount of a peptide having the amino acid sequence of SEQ ID NO:8.

20. A method for treating Type II diabetes in a human in need thereof comprising identifying a human in need of treatment for Type II diabetes and peripherally administering by injection to the human from 0.1 .mu.g/kg/day to 1 .mu.g/kg/day of a peptide having the amino acid sequence of SEQ ID NO:8.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.